Evidence map›Paper›PMID 33981929›Full record

Trial reportPain reports2021

Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.

Jennifer S Gewandter, Robert H Dworkin, Dennis C Turk, John T Farrar, Roger B Fillingim, Ian Gilron, John D Markman, Anne Louise Oaklander, Michael J Polydefkis, Srinivasa N Raja and 23 more

Open access · goldAbstract readClinical TrialReview
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pain reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 5 countries.

Jennifer S GewandterDepartment of Anesthesiology, University of Rochester, Rochester, NY, USA.
Robert H DworkinDepartment of Anesthesiology, University of Rochester, Rochester, NY, USA.
Dennis C TurkUniversity of Washington, Seattle, WA, USA.
John T FarrarUniversity of Pennsylvania, Philadelphia, PA, USA.
Roger B FillingimUniversity of Florida, Gainesville, FL, USA.
Ian GilronQueen's University, Kingston, ON, Canada.
John D MarkmanDepartment of Anesthesiology, University of Rochester, Rochester, NY, USA.
Anne Louise OaklanderHarvard University, Boston, MS, USA.
Michael J PolydefkisJohns Hopkins University, Baltimore, MD, USA.
Srinivasa N RajaJohns Hopkins University, Baltimore, MD, USA.
James P RobinsonUniversity of Washington, Seattle, WA, USA.
Clifford J WoolfHarvard University, Boston, MS, USA.
Dan ZieglerGerman Diabetes Center at Heinrich Heine University, Düsseldorf, Germany.
Michael A AshburnUniversity of Pennsylvania, Philadelphia, PA, USA.
Laurie B BurkeLora Group, LLC, Royal Oak, MD, USA.
Penney CowanAmerican Chronic Pain Association, Rocklin, CA, USA.
Steven Z GeorgeUniversity of Florida, Gainesville, FL, USA.
Veeraindar GoliPfizer and Duke University, Raleigh-Duram, NC, USA.
Ole X GraffGlaxoSmithKline, London, United Kingdom.
Smriti IyengarEli Lilly, Indianapolis, IN, USA.
Gary W JayVirtuous Pharma, Inc, Raleigh-Durham, NC, USA.
Joel KatzYork University, Toronto, ON, Canada.
Henrik KehletRigshospitalet, Copenhagen University, Denmark.
Rachel A KittDepartment of Anesthesiology, University of Rochester, Rochester, NY, USA.
Ernest A KopeckyEndo Pharmaceuticals, Inc, Malvern, PA, USA.
Richard MalamutTeva Pharmaceuticals, North Wales, PA, USA.
Michael P McDermottDepartment of Anesthesiology, University of Rochester, Rochester, NY, USA.
Pamela PalmerAcelRx, Redwood City, CA, USA.
Bob A RappaportArlington, VA, USA.
Christine RauschkolbJohnson and Johnson, Titusville, NJ, USA.
Ilona SteigerwaldGrünenthal GMbH, Aachen, Germany.
Jeffrey TobiasJazz Pharmaceuticals, Palo Alto, CA, USA.
Gary A WalcoUniversity of Washington, Seattle, WA, USA.
University of Rochester · USUniversity of Washington · USHarvard University · USJohns Hopkins University · USUniversity of Florida · USUniversity of Pennsylvania · USAcelRx Pharmaceuticals (United States) · USAmerican Chronic Pain AssociationDeutsches Diabetes-Zentrum e.V. · DEDuke University · USEli Lilly (United States) · USEndo Pharmaceuticals (United States) · USGlaxoSmithKline (United Kingdom) · GBGrünenthal Group (Germany) · DEJazz Pharmaceuticals (United States) · USJohnson & Johnson (United States) · USQueen's University · CARigshospitalet · DKSierra Lobo (United States) · USTeva Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive interventions, an IMMPACT meeting was convened to discuss research design considerations for clinical trials investigating the prevention of chronic pain. We present general design considerations for prevention trials in populations that are at relatively high risk for developing chronic pain. Specific design considerations included subject identification, timing and duration of treatment, outcomes, timing of assessment, and adjusting for risk factors in the analyses. We provide a detailed examination of 4 models of chronic pain prevention (ie, chronic postsurgical pain, postherpetic neuralgia, chronic low back pain, and painful chemotherapy-induced peripheral neuropathy). The issues discussed can, in many instances, be extrapolated to other chronic pain conditions. These examples were selected because they are representative models of primary and secondary prevention, reflect persistent pain resulting from multiple insults (ie, surgery, viral infection, injury, and toxic or noxious element exposure), and are chronically painful conditions that are treated with a range of interventions. Improvements in the design of chronic pain prevention trials could improve assay sensitivity and thus accelerate the identification of efficacious interventions. Such interventions would have the potential to reduce the prevalence of chronic pain in the population. Additionally, standardization of outcomes in prevention clinical trials will facilitate meta-analyses and systematic reviews and improve detection of preventive strategies emerging from clinical trials.

Indexed as

Chemotherapy-induced peripheral neuropathyChronic low back painChronic postsurgical painPostherpetic neuralgiaPrevention trial designRisk factors

Identifiers

PMID33981929
PMCPMC8108588
OpenAlexW3124651197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.